What we do


Cancer cells exhibit altered transcriptional profiles when compared to their tissue of origin. Genetic alterations participate in promoting defective transcription, however they don't explain the full spectrum of aberrations found in malignant tissues. Gene expression is also controlled via modifications of the chromatin landscape including DNA methylation, histone modifications and chromatin remodelling. Our objective is to characterize the role of the chromatin landscape in oncogenesis and to understand how cancer cells reprogram the chromatin landscape to stop the treatment from working.

We have used breast cancer models to demonstrate that epigenetic reprogramming of the chromatin landscape promotes the expression of genes directly related to resistance to endocrine therapies. We can create epigenomic maps to study the regulatory networks of cancer cells and determine how these networks respond to therapies. Ultimately, we want to exploit epigenetic mapping to identify drug-responsive targets, biomarkers and develop novel compounds to interfere with reprogramming.

We are also interested in understanding the extent of interactions existing between genetic and epigenetic alterations. It is likely that cancer cells exploit both genetic and epigenetic mutations to promote proliferation, adaptation and invasion. 

 

What’s going on

Day 11 of #leadinglights and yesterday we had blood being taken by elf Molly, today we have Lottie, a Research Technician processing patient blood samples in the lab at Charing Cross Hospital to send to scientists at ICTEM, Hammersmith Campus... selfless by name and nature 👏🌟

Unreal. The US just joined Russia & Saudi Arabia in refusing to endorse findings of big international report warning of long-term climate catastrophe:

https://t.co/NoCqYFvVoC

This again shows that Trump's *worldview* as basis for big decisions is producing disastrous outcomes: https://t.co/6GKR1qRAM9

Interested in joining a multidisciplinary group studying cancer evolution in London? We are looking for a higher scientific officer to join our Centre for Evolution and Cancer @ICR_London (https://t.co/HsdDovZr5q) to manage our single-cell platforms: https://t.co/GJ8E1BBNOz

For those who do not know already, CAF are important. Thus the particular interest in CAF biology in our lab. #Tumor #Microenvironment
https://t.co/4glFhkGElP

Petition: Grant a People's Vote if Parliament rejects the EU Withdrawal Agreement https://t.co/0hJ77pwhyO

Load More...

News from our lab

Ylenia won the European Association for Cancer Research Meeting Bursary to attend the EACR 25

One of our PhD students, Ylenia Perone, has been awarded the EACR Meeting Bursary giving her the opportunity to travel […]

Our new paper is out. A big thank to all of you !!

Three years of intense work and this is the result!! “Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with […]

Giacomo presenting at the Lindau Nobel Laureate Meeting 2018

Our PhD student Giacomo Corleone is one of the 600 young scientists who will participate to the Nobel Laureate Meeting 2018 […]

See all our news

New facts from the world

Breast cancer awareness month

October is breast cancer awareness month, which is a worldwide annual campaign to increase awareness of the disease and to […]

In the next few years, it will be possible to identify cancers and determine prognosis from a simple blood analysis.

New research published in the journal, Clinical Cancer Research, shows the development of a technique allowing the identification of cancer mutations […]

Science reports in press, so frustrating!!

A light-hearted but insightful satire of why you should be careful of getting your science from the press. Most of […]

Latest scientific discoveries